Danish insulin maker Novo Nordisk has been subpoenaed by the US Attorney for the District of Massachusetts over “potential manufacturing issues” at its Kalundborg location, the company announced on Friday.
According to Reuters, Novo Nordisk’s Kalundborg facility is the world’s largest insulin production site, responsible for about half to the world’s supply.
The company did not release details on the subpoena but said that production would continue in Kalundborg.
“Novo Nordisk is cooperating fully with the US Attorney in this investigation,” the company said in a statement.
“At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information,” it added.
The Danish company recently received the backing of an advisory panel to the US Food and Drug Administration (FDA) for Novo’s obesity drug Saxenda. Although a final decision by the FDA did not come on October 20th as expected, the regulatory agency is still widely expected to approve the drug for the US market, giving Novo Nordisk access to a huge market where around 35 percent of adult Americans are obese.
Novo Nordisk has around 41,000 employees worldwide with 42 percent of them located in Denmark.